AIC
ADMA icon

Archer Investment Corporation’s ADMA Biologics ADMA Stock Holding History

Archer Investment Corporation’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-400
Closed – – 584
2021
Q1 		$0 Buy
+400
New +$915 ﹤0.01% 750

Other funds holding ADMA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Archer Investment Corporation's ADMA Position: Q2 2021 in Review

Archer Investment Corporation sold out of ADMA Biologics (ADMA) in Q2 2021, closing a stake of 400 shares.

Archer Investment Corporation first reported a position in ADMA in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 90 funds tracked by Wall St. Rank hold ADMA as of Q2 2021.

  • Archer Investment Corporation reported no remaining ADMA Biologics position as of Q2 2021 after selling out during the quarter.
  • Archer Investment Corporation sold 400 ADMA Biologics shares in Q2 2021.
  • Archer Investment Corporation first reported a position in ADMA Biologics in Q1 2021 and held it in 1 quarter.
  • Archer Investment Corporation's ADMA Biologics position peaked at $0 in Q1 2021.
  • 90 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2021.

Based on Archer Investment Corporation's 13F filing for Q2 2021, filed 5 Aug 2021.